Managing patients with multiple myeloma during the COVID-19 pandemic: recommendations from an expert panel – ABHH monoclonal gammopathies committe
Queiroz Crusoé, Edvan de
Pessoa de Magalhaes Filho, Roberto Jose
Cordeiro de Farias, Danielle Leão
Braga, Walter Moises
Pinto Neto, Jorge Vaz
Nogueira Ribeiro, Glaciano
MetadataMostrar registro completo
Since the World has been facing the COVID-19 pandemic, special attention has been taken concerning cancer patients; related to their immunosuppression status, adding risk for more aggressive COVID-19 and mortality, but also concerns about the access and the quality of care in cancer therapy. The COVID-19 pandemic impacts the number of infected, its related mortality, as well as the care of cancer patients. Multiple myeloma patients are a particular group with several important aspects to be considered during pandemic times. In essence, they are immunosuppressed in differentintensities during their treatment. Most ofthem are elderly and all of them require long-term therapy, with prolonged contact with the health care system, possibly including a stem cell transplant during the treatment. A panel of experts in multiple myeloma and infectious diseases discusses pieces of evidence and the lack of the same in the scenario of COVID-19 in myeloma patients, while also exposing what is expected for the next phases of the COVID-19 pandemic.
Link para o recursohttps://doi.org/10.1016/j.htct.2020.05.001
Estadísticas Google Analytics
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.